...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of neurology >Penumbra-based radiomics signature as prognostic biomarkers for thrombolysis of acute ischemic stroke patients: a multicenter cohort study
【24h】

Penumbra-based radiomics signature as prognostic biomarkers for thrombolysis of acute ischemic stroke patients: a multicenter cohort study

机译：基于Penumbra的辐射症作为急性缺血性卒中患者溶栓的预后生物标志物：多中心队列研究

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background and Purpose This study aimed at developing a radiomics signature (R score) as prognostic biomarkers based on penumbra quantification and to validate the radiomics nomogram to predict the clinical outcomes for thrombolysis for acute ischemic stroke (AIS) patients. Methods In total, 168 patients collected from seven centers were retrospectively included. A score of mismatch was defined as MIS. Based on a short-term clinical label, 456 radiomics features were evaluated with feature selection methods. R score was constructed with the selected features. To compare the predictive capabilities of the clinical factors, MIS, and R score, three nomograms were developed and evaluated, according to the short-term clinical assessment on day 7. Finally, the radiomics nomogram was validated by predicting the 3-month clinical outcomes of AIS patients, in an external cohort. Results R scores were found to be significantly higher in patients with favorable clinical outcomes in both training and validation datasets. The predictive value of the radiomics nomogram estimating favorable clinical outcomes was modest, with a concordance index (C-index) of 0.695 [95% confidence interval (CI) 0.667-0.723) in an external validation dataset. In addition, the area under curve (AUC) of the radiomics nomogram predicting favorable clinical outcome reached 0.886 (95% CI 0.809-0.963) on day 7 and 0.777 (95% CI 0.666-0.888) at 3 months. Conclusions The radiomics signature is an independent biomarker for estimating the clinical outcomes in AIS patients. By improving the individualized prediction of the clinical outcome for AIS patients 3 months after onset, the radiomics nomogram adds more value to the current clinical decision-making process.
机译：背景和目的本研究旨在基于Penumbra定量的预后生物标志物开发辐射瘤签名（R分数），并验证辐射瘤NOM图预测急性缺血性卒中（AIS）患者的溶栓溶栓临床结果。七个中心收集的总共有168名患者的方法被回顾。不匹配的分数被定义为MIS。基于短期临床标签，采用特征选择方法评价456个射出物特征。 R分数由所选功能构建。为了比较临床因素，MIS和R分数的预测能力，根据第7天的短期临床评估，开发和评估了三种拓图。最后，通过预测3个月的临床结果来验证辐射瘤NOMA图AIS患者，在外部队列中。结果培训和验证数据集的临床结果有利的患者中发现R分数明显高。额外临床结果估计有利临床结果的预测值是适度的，在外部验证数据集中具有0.695的一致性指数（C折射率）0.695 [95％置信区间（CI）0.667-0.723）。此外，在第7天和第3个月的第7天和第0.777天（95％CI 0.666-0.888）中，曲线瘤的曲线（AUC）下的曲线区域（AUC）的区域达到0.886（95％CI 0.80.0.963）。结论辐射瘤签名是一种独立的生物标志物，用于估算AIS患者的临床结果。通过提高AIS患者的临床结果的个体化预测，在发病后3个月，辐射瘤NOM图对目前的临床决策过程增加了更多价值。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号